Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) EBITDA Margin (2019 - 2025)

Revolution Medicines (RVMD) has 6 years of EBITDA Margin data on record, last reported at 2654.81% in Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 2654.81%; the TTM value through Dec 2025 reached 1974.94%, changed N/A, while the annual FY2023 figure was 3748.21%, 304129.0% down from the prior year.
  • EBITDA Margin reached 2654.81% in Q3 2025 per RVMD's latest filing, up from 24256.47% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 2654.81% in Q3 2025 and bottomed at 24256.47% in Q4 2023.
  • Average EBITDA Margin over 4 years is 2993.02%, with a median of 722.9% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: soared 254813bps in 2022, then crashed -2385394bps in 2023.
  • A 4-year view of EBITDA Margin shows it stood at 559.33% in 2021, then increased by 28bps to 402.52% in 2022, then tumbled by -5926bps to 24256.47% in 2023, then skyrocketed by 111bps to 2654.81% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 2654.81% in Q3 2025, 24256.47% in Q4 2023, and 2845.11% in Q2 2023.